TOVX logo

TOVXTheriva Biologics Inc

$0.2552
$0.0273
(9.66%)
Today
Closed $0.2552
$0.0002
(0.08%)
After Hours
Updated: 07:58 PM EDT
Mkt Cap$11.71M
Vol2.48M
News
all
press releases
Rogan’s Runners Market Ignites
The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,
24-7 Market News
News Placeholder
More News
News Placeholder
Regulatory Wins, Capital Flows, and Global Expansion Drive Market Momentum
A wave of regulatory clarity, strategic financing, and global expansion is reshaping pockets of the market, with companies across biotech, mobility, and emerging healthcare infrastructure positioning for outsized growth. $MGRX, $TOVX, $ZYBT, $FFAI, $TGNT
24-7 Market News
News Placeholder
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
Press Releases
News Placeholder
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Press Releases
News Placeholder
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Press Releases
News Placeholder
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Press Releases
News Placeholder
Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01, in combination with standard chemotherapy.
Stocktwits
News Placeholder
TOVX Stock Jumps 30% As New Patent, FDA Designation Boost Investor Sentiment
Theriva recently secured Rare Pediatric Drug Designation (RPDD) from the U.S. FDA for VCN-01, its experimental treatment for retinoblastoma, the most common type of eye cancer in children.
Stocktwits
<
...
1
>

Advertisement|Remove ads.